The premarket stock price increase of 19% for Tempest Therapeutics is directly related to the positive reception of its liver cancer treatment data at a significant medical conference. This kind of news typically generates investor optimism about the company's future prospects, potentially leading to a short-term increase in stock price. The relevance is high as the news is directly about TPST's product, and the importance is significant due to the potential impact on the company's growth and revenue if the treatment proves successful. The confidence level is not at 100% because the long-term effects on the stock price will depend on further developments and market conditions.